MGMT Antibody, clone MT3.1 | EMD Millipore MAB16200 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

EMD Millipore

other brands :

Oncogene Research Products, Calbiochem, Novagen, Merck, Upstate Biotechnology, Chemicon, LINCO, Novabiochem, Guava

product type :

antibody

product name :

MGMT Antibody, clone MT3.1

catalog :

MAB16200

quantity :

100 μg

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

MT3.1

The same clone is also sold as:

Abnova: MAB3442
LifeSpan Biosciences: LS-C95601
Abcam: ab39253

reactivity :

human

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section

citations: 24

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 1d western blot; human; 1:500; loading ...; fig 3b	Abe H, Natsumeda M, Okada M, Watanabe J, Tsukamoto Y, Kanemaru Y, et al. MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. Front Oncol. 2019;9:1568 pubmed publisher
western blot; human; loading ...; fig 3	Ishiguro K, Zhu Y, Lin Z, Penketh P, Shyam K, Zhu R, et al. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines. J Transl Sci. 2016;2:117-124 pubmed
western blot; human; 1 ug/ml; fig s7	Shao H, Chung J, Lee K, Balaj L, Min C, Carter B, et al. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nat Commun. 2015;6:6999 pubmed publisher
immunohistochemistry - paraffin section; human; 1:50	Shilpa V, Bhagat R, Premalata C, Pallavi V, Ramesh G, Krishnamoorthy L. Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer. Indian J Med Res. 2014;140:616-23 pubmed
immunohistochemistry; human	Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, et al. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. J Neurosurg. 2014;121:543-53 pubmed publisher
	Kristensen L, Michaelsen S, Dyrbye H, Aslan D, Grunnet K, Christensen I, et al. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma. J Neuropathol Exp Neurol. 2016;75:246-55 pubmed publisher
	Yamamuro S, Okamoto Y, Sano E, Ochiai Y, Ogino A, Ohta T, et al. Characterization of glioma stem-like cells from human glioblastomas. Int J Oncol. 2015;47:91-6 pubmed publisher
	Michaelsen S, Christensen I, Grunnet K, Stockhausen M, Broholm H, Kosteljanetz M, et al. Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC Cancer. 2013;13:402 pubmed publisher
	Hirano H, Yonezawa H, Yunoue S, Habu M, Uchida H, Yoshioka T, et al. Immunoreactivity of Wnt5a, Fzd2, Fzd6, and Ryk in glioblastoma: evaluative methodology for DAB chromogenic immunostaining. Brain Tumor Pathol. 2014;31:85-93 pubmed publisher
	Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H, et al. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Cancer Lett. 2013;331:68-75 pubmed publisher
	Caldera V, Mellai M, Annovazzi L, Monzeglio O, Piazzi A, Schiffer D. MGMT hypermethylation and MDR system in glioblastoma cancer stem cells. Cancer Genomics Proteomics. 2012;9:171-8 pubmed
	Bobustuc G, Smith J, Maddipatla S, Jeudy S, Limaye A, Isley B, et al. MGMT inhibition restores ER? functional sensitivity to antiestrogen therapy. Mol Med. 2012;18:913-29 pubmed publisher
	Kohsaka S, Wang L, Yachi K, Mahabir R, Narita T, Itoh T, et al. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol Cancer Ther. 2012;11:1289-99 pubmed publisher
	Iliadis G, Kotoula V, Chatzisotiriou A, Televantou D, Eleftheraki A, Lambaki S, et al. Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer. 2012;12:3 pubmed publisher
	Bobustuc G, Baker C, Limaye A, Jenkins W, Pearl G, Avgeropoulos N, et al. Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol. 2010;12:917-27 pubmed publisher
	Borie C, Colas C, Dartigues P, Lazure T, Rince P, Buhard O, et al. The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. Int J Cancer. 2009;125:2360-6 pubmed publisher
	Nakagawa T, Ido K, Sakuma T, Takeuchi H, Sato K, Kubota T. Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology. 2009;29:379-88 pubmed publisher
	Ekeblad S, Sundin A, Janson E, Welin S, Granberg D, Kindmark H, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13:2986-91 pubmed
	Lavon I, Zrihan D, Zelikovitch B, Fellig Y, Fuchs D, Soffer D, et al. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res. 2007;13:1429-37 pubmed
	Will E, Bailey J, Schuesler T, Modlich U, Balcik B, Burzynski B, et al. Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials. Mol Ther. 2007;15:782-91 pubmed
	Nosho K, Yamamoto H, Takahashi T, Mikami M, Taniguchi H, Miyamoto N, et al. Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. Carcinogenesis. 2007;28:1364-70 pubmed
	Takahashi T, Nosho K, Yamamoto H, Mikami M, Taniguchi H, Miyamoto N, et al. Flat-type colorectal advanced adenomas (laterally spreading tumors) have different genetic and epigenetic alterations from protruded-type advanced adenomas. Mod Pathol. 2007;20:139-47 pubmed
	Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer. 2006;106:1759-65 pubmed
	Shen L, Kondo Y, Rosner G, Xiao L, Hernandez N, Vilaythong J, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005;97:1330-8 pubmed

product information

Catalog Number :

MAB16200

Subcategory :

Epigenetics & Nuclear Function

Product Name :

Anti-MGMT Antibody, clone MT3.1

Product Type :

Antibodies

Clonality :

Monoclonal Antibody

Gene ID :

P16455

Host Name :

Mouse

Antigen :

MGMT

Clone :

MT3.1

Conjugate :

Purified

Isotype :

IgG1

Product Description :

Anti-MGMT Antibody, clone MT3.1

Cross Reactivity :

Human

Background :

O6-Methylguanine-DNA Methyltransferase (MGMT) is a ubiquitous DNA repair protein that removes O6-alkyl-guanine, primarily O6 methylguanine lesions from damaged DNA. It is a major contributor to cellular protection from the mutagenic, carcinogenic, and cytotoxic effects of DNA alkylation. The mechanism of MGMT action is based on the transfer of the alkyl group from the DNA to a unique acceptor cysteine residue in the protein, forming a stable thioether linkage. MGMT is frequently classified as a suicide protein. The repair capacity for O6- methylguanine is dependent on the number of MGMT molecules in the cell. There is a correlation between the occurrence of cancer in various tissues and the lack of the MGMT enzyme. High levels of MGMT result in reduced tumor events and resistance of tumors to alkylating agents.

ALT Names :

O-6-methylguanine-DNA Methyltransferase;Methylated-DNA--Protein-cysteine Methyltransferase

Immunogen :

Made against recombinant human MGMT (O-6-methylguanine-DNA methyltransferase) expressed in E. coli.

Specificity :

MGMT is a 22 kDa DNA repair protein that is present in all normal tissues; however, in a subset of human tumours MGMT is completely absent. Thus, antibody MAB16200 may be helpful in utilizing MGMT as a marker of malignant or pre-malignant cells. Because MGMT repairs the potentially cytotoxic antitumour lesions induced in DNA by certain cancer chemotherapeutic alkylating agents (e.g. BCNU, CCNU, DTIC, procarbazinc, temozolomide), tumours lacking or having low levels of MGMT will predictably be responsive to drug therapy. Conversely, tumours with high MGMT levels will likely be drug resistant. The MGMT antibody may also be used to gauge the effectiveness of MGMT modulators, such as O-6-benzylguanine, which lead to rapid degradation of the inactivated protein.

Package Size :

100 μg

Uses :

Flow Cytometry;Immunocytochemistry;Immunohistochemistry (Paraffin);Immunoprecipitation;Western Blotting

Storage :

Stable for 1 year at 2-8ºC from date of receipt.